Lawyers react to Myriad decision
Friday’s much anticipated decision in Association for Molecular Pathology v the USPTO and Myriad Genetics came as a relief to those who feared an outcome that would undo “essential building blocks” of the biotech industry, said patent lawyers
“[A decision in favour of AMP] could have had devastating consequences in terms of lack of investor confidence in the industry,” said Gerald Flattmann of Paul Hastings. Flattmann added that it could have “perhaps demoted the US from its premier...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.